Tenaya’s Highly Selective HDAC6 Inhibitor TN-301 Outperformed Approved Pan-HDAC Inhibitor Givinostat in Improving Muscle Function and Correcting Drivers of DMD Cardiomyopathy  New Data Confirm TN-301’s Differentiated Mechanism and Opportunities to Positively Address Rare and Prevalent Cardiac, Metabolic and Muscular Conditions Tenaya Plans to Advance TN-301 Toward Phase 2 Clinical Development ORLANDO, Fla. and SOUTH SAN FRANCISCO, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: ...

Tenaya’s Highly Selective HDAC6 Inhibitor TN-301 Outperformed Approved Pan-HDAC Inhibitor Givinostat in Improving Muscle Function and Correcting Drivers of DMD Cardiomyopathy New Data Confirm TN-301’s Differentiated Mechanism and Opportunities to Positively Address Rare and Prevalent Cardiac, Metabolic and Muscular Conditions Tenaya Plans to Advance TN-301 Toward Phase 2 Clinical Development ORLANDO, Fla. and SOUTH SAN FRANCISCO, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: ...

Core Insights - JCR Pharmaceuticals and Italfarmaco have entered into an exclusive licensing agreement for the development and commercialization of givinostat in Japan [1] Company Summary - JCR Pharmaceuticals is collaborating with Italfarmaco to enhance the market presence of givinostat in Japan through this exclusive licensing deal [1] - The agreement signifies a strategic partnership aimed at leveraging both companies' strengths in the pharmaceutical sector [1] Industry Summary - The licensing agreement reflects ongoing trends in the pharmaceutical industry where companies seek partnerships to expedite drug development and market entry [1] - Givinostat is positioned to address specific medical needs in Japan, indicating potential growth opportunities within the local market [1]